This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
VIA AILooking for an interpreter?
Remoto by ProZ.com connects you with an identity-verified interpreter by video or phone in about 60 seconds — 300+ languages, on demand or booked ahead.
Try Remoto »
Working languages:
English to Latvian Russian to Latvian Latin to Latvian
Client-vendor relationship recorded successfully!
Doroteja has been added to your list of hired vendors.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Access to Blue Board comments is restricted for non-members. Click the outsourcer name to view the Blue Board record and see options for gaining access to this information.
Natalizumab is a selective adhesion-molecule inhibitor and binds to the α4 subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils. Specifically, natalizumab binds to the α4β1 integrin, blocking the interaction with its cognate receptor, vascular cell adhesion molecule 1 (VCAM 1), and ligands osteopontin, and an alternatively spliced domain of fibronectin, connecting segment 1 (CS 1). Natalizumab blocks the interaction of α4β7 integrin with the mucosal addressin cell adhesion molecule 1 (MadCAM 1). A further mechanism of action of natalizumab may be to suppress ongoing inflammatory reactions in diseased tissues by inhibiting the interaction of α4 expressing leukocytes with their ligands in the extracellular matrix and on parenchymal cells. As such, natalizumab may act to suppress inflammatory activity present at the disease site, and inhibit further recruitment of immune cells into inflamed tissues.
In Crohn’s disease the interaction of both the 41 and 47 integrins with the endothelial receptors VCAM-1 and MadCAM-1 are important contributors to the chronic inflammation that is a characteristic of the disease. MadCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T lymphocytes to gut lymph tissue found in Peyer’s patches. Under normal conditions, VCAM-1 is not normally expressed on gut endothelial cells. However in the presence of pro-inflammatory cytokines, VCAM-1 is upregulated in response to inflammatory cytokines in the setting of Crohn’s disease. Disruption of these cell adhesion molecule interactions prevents trafficking of mononuclear leukocytes across the endothelium and into the parenchymal tissue. In addition, the inhibition of the 4-subunit blocks the interaction of leukocytes with the gut extracellular matrix, including osteopontin and epitopes of fibronectin (FN). This may help suppress existing inflammation within the gut tissue.
Translation - Latvian Farmakodinamiskās īpašības
Natalizumabs ir selektīvas molekulārās adhēzijas inhibitors, un tas piesaista cilvēka integrīna α4-subvienību, kura ievērojamos daudzumos ir sastopama uz visu leikocītu, izņemot neitrofīlo virsmas. Natalizumabs specifiski piesaistās α4β1 integrīnam, bloķējot mijiedarbību ar tam radniecisko receptoru, asinsvadu šūnu piesaistīšanas molekulu-1 (VCAM 1), ligandu osteopontīnu un alternatīvi savīto domēnu fibronektīnu, tā savienošanās segmentu-1(CS 1). Natalizumabs bloķē α4β7 integrīna mijiedarbību ar tā gļotādu šūnu adhēzijas molekulu-1 (MadCAM 1). Šīs molekulārās mijiedarbības pārraušana novērš vienkodola leikocītu pārvietošanos cauri endotēlijam iekaisušajos parenhīmas audos. Turpmākais natalizumaba darbības mehānisms varētu būt esošo iekaisuma reakciju nomākšana slimajos audos, kavējot α4 leikocītu mijiedarbību ar to ligandiem parenhīmas šūnu ārpusšūnu matricē un parenhīmas šūnās. Šādā veidā natalizumabs var darboties nomācoši uz iekaisuma reakcijām slimajā vietā un kavēt turpmāku imūnsistēmas šūnu nonākšanu iekaisušajos audos.
Krona slimības gadījumos, mijiedarbība starp abiem 41 un 47 integrīniem un endotēlija receptoriem VCAM-1 un MadCAM-1 ir nozīmīgs šai slimībai raksturīgo hronisku iekaisumu veicinošais faktors. MadCAM-1 galvenokārt izdala zarnu endotēlija šūnas un tam ir ārkārtīgi nozīmīga loma T limfocītu piesaistē zarnu limfātiskajiem audiem Peijera plātnītēs. Normālos apstākļos zarnu endotēlija šūnas parasti neizdala VCAM-1. Tomēr, iekaisumu attīstību veicinošo citokīnu klātbūtnē tiek aktivizēts VCAM-1, tādējādi reaģējot uz iekaisuma citokīnu iedarbību, attīstoties Krona slimībai. Šīs šūnu adhēzijas molekulārās mijiedarbības pārtraukšana novērš vienkodola leikocītu pārvietošanos cauri endotēlijam un iekaisušajos parenhīmas audos. Bez tam, 4-subvienības inhibīcija bloķē leikocītu mijiedarbību zarnu ārpusšūnu matriksā, t.sk. osteopontīna un fibronektīna epitopu (FN). Tas var palīdzēt nomākt iekaisuma procesus zarnu audos.
More
Less
Translation education
Master's degree - Ventspils University, Latvia
Experience
Years of experience: 28. Registered at ProZ.com: Jan 2005.
Adobe Acrobat, Microsoft Excel, Microsoft Word, Powerpoint, Trados Studio
Bio
Medical, pharmaceutical translations, linguistic validation
Keywords: Medical, pharmaceutical translations
Chemistry, biochemistry, medicine, pharmaceuticals, veterinary medicine, veterinary science, linguistic validation, cognitive debriefing, Summaries for Product Characteristics) and PILs (Patient Information Leaflets). See more.Medical, pharmaceutical translations
Chemistry, biochemistry, medicine, pharmaceuticals, veterinary medicine, veterinary science, linguistic validation, cognitive debriefing, Summaries for Product Characteristics) and PILs (Patient Information Leaflets), Clinical study documentation. See less.
